Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 9:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 160 matching trials from the live ClinicalTrials.gov search.
Conditions
Uterine Fibroids
Interventions
radiofrequency ablation
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Sacramento, California
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Post Market Evaluation of Acessa With TAG

NCT01842789
Conditions
Uterine Fibroids
Interventions
Acessa Procedure
Device
Lead sponsor
Acessa Health, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
San Ramon, California
Completed Phase 3 Interventional Accepts healthy volunteers Results available

MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication

NCT00365989
Conditions
Uterine Leiomyoma, Uterine Fibroids
Interventions
ExAblate Enhanced Sonication
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
4
States / cities
La Jolla, California • Burlington, Massachusetts • Kalamazoo, Michigan + 1 more
Conditions
Uterine Fibroids, Uterine Leiomyomata
Interventions
Philips MR guided HIFU system
Device
Lead sponsor
Philips Healthcare
Industry
Eligibility
18 Years to 59 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • Houston, Texas
Conditions
Leiomyoma
Interventions
CDB-2914
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
33 Years to 50 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Leiomyoma
Interventions
ExAblate 2000
Device
Lead sponsor
InSightec
Industry
Eligibility
Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk
Interventions
Relugolix + Estradiol + Norethindrone Acetate
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Marlborough, Massachusetts
Completed No phase listed Observational Accepts healthy volunteers

Biologic Predictors of Leiomyoma Treatment Outcomes

NCT01936493
Conditions
Uterine Leiomyomas, Fibroids, Uterine Fibroids, Myomas
Interventions
DNA analysis, Hormonal analysis
Genetic · Other
Lead sponsor
Elizabeth A. Stewart
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Uterine Fibroids
Interventions
Placebo, Telapristone Acetate
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Fort Lauderdale, Florida • Sandy Springs, Georgia • Metairie, Louisiana + 4 more
Conditions
Cholecystitis, Endometriosis, Bowel Obstruction, Fibroids, Prostate Cancer, Chronic Kidney Disease, Uterine Prolapse
Interventions
Deep to Moderate NMB, Moderate to Deep NMB, Rocuronium
Procedure · Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
Uterine Fibroids
Interventions
Vilaprisan (BAY1002670), Standard of care
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
94
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 76 more
Recruiting No phase listed Observational Accepts healthy volunteers

Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

NCT00005095
Conditions
Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2), Ovarian Cancer, Sarcoma, Uterine Leiomyomata, Vaginal Cancer, Vulvar Cancer
Interventions
Ca-125, screening questionnaire administration, Surgery
Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2040
U.S. locations
1
States / cities
Chicago, Illinois
Completed Not applicable Interventional Results available

MyoSure Hysteroscopic Tissue Removal System Registry Study

NCT01369758
Conditions
Uterine Fibroids, Polyps
Interventions
MyoSure Tissue Removal System
Device
Lead sponsor
Hologic, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Marlborough, Massachusetts
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
103
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 89 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry

NCT02100904
Conditions
Uterine Fibroids
Interventions
Radiofrequency ablation of fibroids, Myomectomy of fibroids
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older · Female only
Enrollment
578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
12
States / cities
Irvine, California • San Diego, California • San Francisco, California + 9 more
Conditions
Fertility Issues
Interventions
Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)
Device
Lead sponsor
Turtle Health, Inc.
Industry
Eligibility
18 Years to 49 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Contraception
Interventions
Relugolix Combination Therapy
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
109
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 89 more
Withdrawn Not applicable Interventional Accepts healthy volunteers

Holistic Medicine Treatment of Uterine Fibroids-Adults

NCT07219381
Conditions
Uterine Fibroids - 1St Diagnosis, Uterine Fibroids Affecting Pregnancy, Uterine Fibroid Degenerated
Interventions
Holistic Medicine (HM)
Behavioral
Lead sponsor
Virtual Tribunal Monastery
Other
Eligibility
22 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Anchorage, Alaska
Conditions
Leiomyoma
Interventions
Dexamethasone, Saline
Drug
Lead sponsor
University of Miami
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Miami, Florida
Conditions
Heavy Menstrual Bleeding, Uterine Fibroids
Interventions
Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo, Elagolix Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
155
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more
Conditions
Endometrial Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Leiomyoma
Interventions
Not listed
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years and older · Female only
Enrollment
7,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Detroit, Michigan • Durham, North Carolina + 3 more
Conditions
Uterine Fibroids
Interventions
Proellex 25 mg, Proellex 50 mg, Lupron Depot
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Sarasota, Florida • Houston, Texas
Conditions
Uterine Fibroids
Interventions
Proellex 25 mg, Proellex 50 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
25
States / cities
Little Rock, Arkansas • Beverly Hills, California • San Diego, California + 17 more
Conditions
Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Metastatic Renal Cell Carcinoma, Skin Leiomyoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Uterine Corpus Leiomyoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Mercaptopurine, Questionnaire Administration, Skin Biopsy
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Los Angeles, California